This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Fa Liu, PhD
Chief Scientific Officer at Full-Life Technologies


Dr. Liu is the CSO of Full-Life Technologies, which centers on targeted alpha-radionuclide therapies. Prior to joining Full-Life, he was the CEO and Co-founder of Focus-X Therapeutics (2020-2022), a radioligand therapy company recently acquired by Full-Life. Before founding Focus-X, Dr. Liu headed the Chemistry of Novo Nordisk US sites, and Calibrium LLC (acquired by Novo Nordisk) (2014-2020), and served as a Group Leader at the Eli Lilly Peptide Discovery (2009-2014). Prior to Lilly, Dr. Liu worked at National Cancer Institute as a Staff Scientist (2004-2009). He received his Ph.D. in Synthetic Organic Chemistry from Shanghai Institute of Organic Chemistry in 2004.

Agenda Sessions

  • Ac-FL-020, A Novel PSMA-targeting Radioligand Therapy Candidate in Development